Interim PET for prognosis in adults with Hodgkin lymphoma: A prognostic factor exemplar review

Interim PET for prognosis in adults with Hodgkin lymphoma: A prognostic factor exemplar review

This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows: Primary objective: The objective of this systematic review is to identify all studies evaluating interim PET scan results as a prognostic factor, describe the characteristics and risk of bias of included studies and...

Detaylı Bibliyografya
Asıl Yazarlar:	Skoetz, N, Collins, G, Moons, K, Estcourt, L, Engert, A, Kobe, C, von Tresckow, B, Trivella, M
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	Wiley 2017

Benzer Materyaller

Interim PET‐results for prognosis in adults with Hodgkin lymphoma: A systematic review and meta‐analysis of prognostic factor studies
Yazar:: Aldin, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
Yazar:: Aldin, A, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

P026 (0057) INTERIM- PET RESULTS FOR PROGNOSIS IN ADULTS WITH HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR EXEMPLAR REVIEW (PRELIMINARY RESULTS)
Baskı/Yayın Bilgisi: (2018-10-01)

Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis (Protocol)
Yazar:: Skoetz, N, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
Yazar:: Akram Al-Ibraheem, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
Yazar:: M. André, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions.
Yazar:: Thomas W Georgi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
Yazar:: Karan L. Chohan, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Simvastatin-dependent apoptosis in Hodgkin’s lymphoma cells and growth impairment of human Hodgkin’s tumors in vivo
Yazar:: Bastian von Tresckow, ve diğerleri
Baskı/Yayın Bilgisi: (2007-05-01)

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.
Yazar:: Thomas W Georgi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
Yazar:: M. C. Pirosa, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
Yazar:: Dennis A. Eichenauer, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD
Yazar:: Diego Villa, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
Yazar:: Johanna Grund, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment
Yazar:: Elizabeth Katherine Anna Triumbari, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
Yazar:: Chiara Rusconi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
Yazar:: Arun Seshachalam, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL
Yazar:: P. Bröckelmann, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET
Baskı/Yayın Bilgisi: (2018-10-01)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
Yazar:: Chiara Rusconi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

The role of FDG-PET in Hodgkin lymphoma
Yazar:: Edyta Subocz, ve diğerleri
Baskı/Yayın Bilgisi: (2017-06-01)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
Yazar:: Jesko Momotow, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
Yazar:: Eleonora Calabretta, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
Yazar:: Annarosa Cuccaro, ve diğerleri
Baskı/Yayın Bilgisi: (2014-07-01)

Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma
Yazar:: Zhou Y, ve diğerleri
Baskı/Yayın Bilgisi: (2019-07-01)

The utility of PET/CT with 18F-FDG in the study of Hodgkin's lymphoma and non-Hodgkin's lymphoma
Yazar:: Marta Milhões, ve diğerleri
Baskı/Yayın Bilgisi: (2015-11-01)

THE CHEMOKINE CCL17/TARC AS A BIOMARKER IN HODGKIN LYMPHOMA
Yazar:: Maike Sauer, ve diğerleri
Baskı/Yayın Bilgisi: (2013-08-01)

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
Yazar:: Tseng Diane, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Evidence of Inbreeding in Hodgkin Lymphoma.
Yazar:: Hauke Thomsen, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA
Yazar:: Dennis A Eichenauer, ve diğerleri
Baskı/Yayın Bilgisi: (2011-10-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
Yazar:: Dennis A. Eichenauer, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
Yazar:: Paul Bröckelmann, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria
Yazar:: Elske Quak, ve diğerleri
Baskı/Yayın Bilgisi: (2014-06-01)

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
Yazar:: Esther Natalie Oliva, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
Yazar:: O. Novosad, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

MRI versus CT and PET/CT in the Preoperative Assessment of Hodgkin and Non-Hodgkin Lymphomas
Yazar:: Francesca Maccioni, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma
Yazar:: Özgür Ömür, ve diğerleri
Baskı/Yayın Bilgisi: (2014-03-01)

Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
Yazar:: Sun H, ve diğerleri
Baskı/Yayın Bilgisi: (2019-11-01)

Suicide in European Hodgkin Lymphoma Patients
Yazar:: Austin I. Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review
Yazar:: Christine Herbst, ve diğerleri
Baskı/Yayın Bilgisi: (2010-03-01)